Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fresh Australian Industry Pact Will Insure Against Shortages

New Five-Year Strategic Agreement Signed Between Government And GBMA

Executive Summary

A fresh five-year strategic agreement struck between Australian off-patent industry association the GBMA and the country’s government offers sustainability and stability for Australia’s generics sector, with the body committing to holding safety stocks of certain drugs within the country to protect against potential shortages in the context of the COVID-19 pandemic.

You may also be interested in...

Medicines For Europe Calls For A Medicines Security Act

The EU would benefit from the creation of a Medicines Security Act to enable equitable access to affordable medicines and active pharmaceutical ingredients across the bloc, Medicines for Europe has said.

Australia’s GBMA Emphasizes Biosimilars Amid Government Change

As Australia’s GBMA launches its latest Biosimilars Awareness Week – the last under a five-year education grant – the association says it is looking forward to “the dawn of a new era” as it begins working with the newly-elected Labor government.

Australia's Competition Regulator Authorizes Another Year Of Close Collaboration

Australian off-patent industry association GBMA and brand body Medicines Australia can continue to collaborate closely as part of work to mitigate shortages in the context of the COVID-19 pandemic, the Australian Competition and Consumer Commission has decided, extending an existing authorization by a further year.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts